Roivant Sciences Ltd

Regeneron Pharmaceuticals is compared against key competitors in the Biotechnology industry, revealing lower P/E, P/B, and P/S ratios suggesting potential undervaluation, but a low ROE indicating lower profitability efficiency. High EBITDA and gross profit levels show strong operational performance, while low revenue growth may be a concern.

Regeneron Pharmaceuticals' PE, PB, and PS ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability, but low revenue growth raises concerns about future performance.

AbbVie's P/E ratio of 63.7 is 1.1x the industry norm, suggesting higher valuation. Its P/B ratio of 49.63 is 7.93x the average, indicating potential overvaluation. With a P/S ratio of 6.14, it's undervalued relative to sales. AbbVie's ROE of 18.4% is 14.39% above the industry average, showing efficient profit generation. EBITDA of $5.0B and gross profit of $10.26B are 5.21x and 5.03x the industry average, respectively, highlighting strong profitability. However, revenue growth of 4.31% is significantly lower than the industry average of 31.36%, suggesting potential sales decline.

Regeneron Pharmaceuticals' PE, PB, and PS ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability. However, low revenue growth raises concerns about market expansion.

Regeneron Pharmaceuticals' P/E, P/B, and P/S ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability, but low revenue growth raises concerns about future performance.